NUS Nu Skin Enterprises Inc

Nu Skin Enterprises Inc. (NYSE: NUS) today announced third quarter results in line with guidance.

Executive Summary Q3 2024 vs. Prior-year Quarter

Revenue

$430.1 million; (13.8)%

• (3.4)% FX impact or $(16.7) million
• Rhyz revenue $73.1 million; 20.9%

Earnings Per Share (EPS)

$0.17 compared to $(0.74) or $0.56 excluding an inventory write-off

Customers

831,768; (15)%

Paid Affiliates

149,264; (20)% or (11)% excluding an adjustment to eligibility requirements

Sales Leaders

38,284; (19)%

“During the third quarter, we achieved results within our previous guidance range with challenges in the core business partially offset by continued strong growth in our Rhyz segment,” said Ryan Napierski, Nu Skin president and CEO. “While we continue to face macroeconomic pressures and challenges within the direct selling industry, our immediate focus is to strengthen the Nu Skin core with a revised business model intended to improve channel activation and customer growth beginning with North America and South Korea this quarter. In addition, we are introducing a streamlined operating framework to improve profitability with an adjusted pricing model to improve customer penetration in developing markets starting with Latin America and certain markets in Southeast Asia, and an accelerated product portfolio optimization plan to improve overall gross margin globally. We also continue to empower growth in our Rhyz businesses with impressive results coming from Mavely and our manufacturing companies.”

Q3 2024 Year-over-year Operating Results

Revenue

$430.1 million compared to $498.8 million

• (3.4)% FX impact or $(16.7) million
• Rhyz revenue $73.1 million; 20.9%

Gross Margin

70.1% compared to 58.6% or 71.8% excluding an inventory write-off

• Nu Skin business was 76.5% compared to 61.8% or 76.8% excluding an inventory write-off

Selling Expenses

39.0% compared to 37.6%

• Nu Skin business was 43.5% compared to 41.7%
  • Includes expense for biannual sales conferences

G&A Expenses

26.9% compared to 26.2%

Operating Margin

4.2% compared to (5.3)% or 7.9% excluding an inventory write-off

Interest Expense

$6.5 million compared to $7.5 million

Other Income/(Expense)

$1.6 million compared to $(0.6) million

Income Tax Rate

37.6% compared to (7.3)% or 10.1% excluding an inventory write-off

EPS

$0.17 compared to $(0.74) or $0.56 excluding an inventory write-off

Stockholder Value

Dividend Payments

$3.0 million

Stock Repurchases

$0.0 million

• $162.4 million remaining in authorization

Q4 and Full-year 2024 Outlook

Q4 2024 Revenue

$410 to $445 million; (16)% to (9)%

• Approximately (2) to (1)% FX impact

Q4 2024 EPS

$(0.09) to $0.01 or $0.19 to $0.29 non-GAAP

2024 Revenue

$1.70 to $1.73 billion; (14)% to (12)%

• Approximately (4) to (3)% FX impact

2024 EPS

$(2.32) to $(2.22) or $0.65 to $0.75 non-GAAP

“As part of our cost-efficiency program, during the quarter we saved an additional $15 million in general and administrative expense and remain on track to meet the high end of our range of $45 to $65 million for 2024,” said James D. Thomas, chief financial officer. “During the quarter, we generated $31.4 million in cash from operations, reduced inventory levels $43 million year over year and paid down debt to further strengthen our balance sheet. Given ongoing pressures in the core Nu Skin business, we are adjusting our 2024 outlook. We now anticipate 2024 revenue in the range of $1.70 to $1.73 billion, with earnings per share of $(2.32) to $(2.22) or $0.65 to $0.75 excluding restructuring and impairment charges. For Q4, we are forecasting projected revenue of $410 to $445 million and earnings per share of $(0.09) to $0.01 or $0.19 to $0.29 excluding planned restructuring charges.”

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Nov. 21, 2024.

About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro environment and the company’s performance, growth and growth opportunities, strategies, initiatives, areas of focus, sales force, shareholder value, product previews and launches, product portfolio optimization, transformation, evolution, operational and financial initiatives, digital tools and initiatives, new market expansion, and plans for developing and emerging markets; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “become,” “plan,” accelerate,” “project,” “continue,” “outlook,” “guidance,” “improve,” “enhance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;
• risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
• economic conditions and events globally;
• competitive pressures in the company’s markets;
• risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
• adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
• political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
• risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
• uncertainties regarding the future financial performance of the businesses the company has acquired;
• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
• regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and
• the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, gross margin, operating margin and income tax rate, each excluding restructuring and impairment charges and/or inventory write-off charges, also are non-GAAP financial measures. Restructuring and impairment charges and inventory write-off charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin and income tax rate calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended September 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

Three Months Ended

September 30,

 

 

Constant-

Currency

 

2024

 

2023

 

Change

 

Change

Nu Skin

Americas

$

77,194

 

$

91,671

 

(15.8)%

0.1%

Southeast Asia/Pacific

 

59,515

 

68,743

 

(13.4)%

(13.2)%

Mainland China

 

53,020

 

 

70,225

 

(24.5)%

(25.4)%

Japan

 

47,222

 

 

53,399

 

(11.6)%

(8.9)%

South Korea

 

45,201

 

 

63,709

 

(29.1)%

 

(27.1)%

Europe & Africa

 

38,577

 

 

50,048

 

(22.9)%

(23.6)%

Hong Kong/Taiwan

 

33,749

 

 

40,724

 

(17.1)%

(16.4)%

Nu Skin other

 

2,518

 

 

(274)

 

1,019.0%

 

1,019.0%

Total Nu Skin

356,996

438,245

(18.5)%

(14.7)%

Rhyz Investments

 

 

Manufacturing

51,773

49,714

4.1%

4.1%

Rhyz other

21,376

10,813

97.7%

97.7%

Total Rhyz Investments

73,149

60,527

20.9%

20.9%

Total

$

430,145

 

$

498,772

 

(13.8)%

(10.4)%

The following table sets forth revenue for the nine-month periods ended September 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

Nine Months Ended

September 30,

 

 

Constant-

Currency

 

2024

 

2023

 

Change

 

Change

Nu Skin

Americas

$

237,160

 

$

300,469

 

(21.1)%

(12.1)%

Southeast Asia/Pacific

 

179,921

 

200,317

 

(10.2)%

(7.4)%

Mainland China

 

178,797

 

 

226,563

 

(21.1)%

(19.2)%

Japan

 

134,045

 

 

156,867

 

(14.5)%

(6.5)%

South Korea

 

130,283

 

 

187,719

 

(30.6)%

 

(28.0)%

Europe & Africa

 

121,564

 

 

144,460

 

(15.8)%

(16.0)%

Hong Kong/Taiwan

 

98,061

 

 

112,380

 

(12.7)%

(10.8)%

Nu Skin other

 

3,186

 

 

208

 

1,431.7%

 

1,431.7%

Total Nu Skin

1,083,017

1,328,983

(18.5)%

(14.3)%

Rhyz Investments

 

 

Manufacturing

153,548

131,032

17.2%

17.2%

Rhyz other

49,967

20,476

144.0%

144.0%

Total Rhyz Investments

203,515

151,508

34.3%

34.3%

Total

$

1,286,532

 

$

1,480,491

 

(13.1)%

(9.3)%

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended September 30, 2024, and 2023:

Three Months Ended

September 30,

2024

 

2023

Change

Customers

 

 

 

 

 

Americas

211,583

231,215

(8)%

Southeast Asia/Pacific

86,307

111,151

(22)%

Mainland China

148,402

189,221

(22)%

Japan

112,257

114,316

 

(2)%

South Korea

90,248

109,550

(18)%

Europe & Africa

135,291

169,320

(20)%

Hong Kong/Taiwan

47,680

54,134

(12)%

Total Customers

831,768

978,907

(15)%

 

 

Paid Affiliates

 

 

 

 

 

Americas

28,772

32,769

(12)%

Southeast Asia/Pacific(1)

26,749

33,574

(20)%

Mainland China

22,843

27,509

(17)%

Japan(1)

22,623

37,695

(40)%

South Korea

20,774

24,110

(14)%

Europe & Africa

16,556

19,254

(14)%

Hong Kong/Taiwan

10,947

11,251

(3)%

Total Paid Affiliates

149,264

186,162

(20)%

 

 

Sales Leaders

 

 

 

 

 

Americas

6,450

7,537

(14)%

Southeast Asia/Pacific

5,398

6,351

(15)%

Mainland China

9,348

12,647

(26)%

Japan

6,866

7,087

(3)%

South Korea

4,388

6,436

(32)%

Europe & Africa

3,318

4,105

(19)%

Hong Kong/Taiwan

2,516

2,868

(12)%

Total Sales Leaders

38,284

47,031

(19)%

 

(1) The September 30, 2024, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters.

 

• “Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

• “Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

• “Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2024

 

2023

 

2024

 

2023

Revenue

$

430,145

 

$

498,772

 

$

1,286,532

 

$

1,480,491

Cost of sales

 

128,682

 

 

206,505

 

 

383,828

 

 

475,635

Gross profit

 

301,463

 

 

292,267

 

 

902,704

 

 

1,004,856

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Selling expenses

 

167,612

 

 

187,750

 

 

486,617

 

 

561,039

General and administrative expenses

 

115,620

 

 

130,882

 

 

358,107

 

 

401,825

Restructuring and impairment expenses

—

—

156,484

9,787

Total operating expenses

 

283,232

 

 

318,632

 

 

1,001,208

 

 

972,651

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

18,231

 

 

(26,365)

 

 

(98,504)

 

 

32,205

Interest expense

 

6,500

 

 

7,535

 

 

20,545

 

 

18,192

Other income (expense), net

 

1,567

 

 

(551)

 

 

1,800

 

 

3,237

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before provision for income taxes

 

13,298

 

 

(34,451)

 

 

(117,249)

 

 

17,250

Provision (benefit) for income taxes

 

4,996

 

 

2,504

 

 

(6,760)

 

 

15,937

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

$

8,302

 

$

(36,955)

 

$

(110,489)

 

$

1,313

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.17

 

$

(0.74)

 

$

(2.23)

 

$

0.03

Diluted

$

0.17

 

$

(0.74)

 

$

(2.23)

 

$

0.03

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding (000s):

 

 

 

 

 

 

 

 

 

 

 

Basic

 

49,707

 

 

49,859

 

 

49,645

 

 

49,812

Diluted

 

49,733

 

 

49,859

 

 

49,645

 

 

50,029

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

 

 

 

 

 

September 30,

2024

 

December 31,

2023

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

227,751

 

$

256,057

Current investments

 

10,077

 

 

11,759

Accounts receivable, net

 

68,812

 

 

72,879

Inventories, net

 

247,789

 

 

279,978

Prepaid expenses and other

 

98,942

 

 

81,198

Total current assets

 

653,371

 

 

701,871

 

 

 

 

 

 

Property and equipment, net

 

410,673

 

 

432,965

Operating lease right-of-use assets

85,550

90,107

Goodwill

 

99,885

 

 

230,768

Other intangible assets, net

 

85,266

 

 

105,309

Other assets

 

248,150

 

 

245,443

Total assets

$

1,590,895

 

$

1,806,463

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

$

32,736

 

$

43,505

Accrued expenses

 

246,615

 

 

260,366

Current portion of long-term debt

 

60,000

 

 

25,000

Total current liabilities

 

339,351

 

 

328,871

 

Operating lease liabilities

 

68,351

 

 

70,943

Long-term debt

 

373,470

 

 

478,040

Other liabilities

 

94,848

 

 

106,641

Total liabilities

 

876,020

 

 

984,495

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued

 

91

 

 

91

Additional paid-in capital

 

624,665

 

 

621,853

Treasury stock, at cost – 40.9 million and 41.1 million shares

 

(1,563,878)

 

 

(1,570,440)

Accumulated other comprehensive loss

 

(105,040)

 

 

(100,006)

Retained earnings

 

1,751,037

 

 

1,870,470

Total stockholders' equity

 

706,875

 

 

821,968

Total liabilities and stockholders’ equity

$

1,582,895

 

$

1,806,463

NU SKIN ENTERPRISES, INC.

Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin

(in thousands, except for per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2024

 

2023

 

2024

 

2023

Gross Profit

 

$

301,463

 

$

292,267

 

$

902,704

 

$

1,004,856

Impact of inventory write-off

 

 

-

 

 

65,728

 

 

-

 

 

65,728

Adjusted Gross Profit

 

$

301,463

 

$

357,995

 

$

902,704

 

$

1,070,584

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin

 

 

70.1%

 

 

58.6%

 

 

70.2%

 

 

67.9%

Gross Margin, excluding inventory write-off impact

 

 

70.1%

 

 

71.8%

 

 

70.2%

 

 

72.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

430,145

 

$

498,772

 

$

1,286,532

 

$

1,480,491

 

NU SKIN ENTERPRISES, INC.

Reconciliation of Core Nu Skin Business Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin

(in thousands, except for per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

September 30,

 

 

 

 

2024

 

2023

 

 

 

 

Gross Profit

 

$

273,155

 

$

270,630

 

 

 

 

 

 

Impact of inventory write-off

 

 

-

 

 

65,728

 

 

 

 

 

 

Adjusted Gross Profit

 

$

273,155

 

$

336,358

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin

 

 

76.5%

 

 

61.8%

 

 

 

 

 

 

Gross Margin, excluding inventory write-off impact

 

 

76.5%

 

 

76.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

356,996

 

$

438,245

 

 

 

 

 

 

NU SKIN ENTERPRISES, INC.

Reconciliation of Operating Margin Excluding Impact of Inventory Write-off, Restructuring and Impairment to GAAP Operating Margin

(in thousands, except for per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2024

 

2023

 

2024

 

2023

Operating Income

 

$

18,231

 

$

(26,365)

 

$

(98,504)

 

$

32,205

Impact of restructuring and impairment

 

 

-

 

 

-

 

 

156,484

 

 

9,787

Impact of inventory write-off

 

 

-

 

 

65,728

 

 

-

 

 

65,728

Adjusted operating income

 

$

18,231

 

$

39,363

 

$

57,980

 

$

107,720

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating margin

 

 

4.2%

 

 

(5.3)%

 

 

(7.7)%

 

 

2.2%

Operating margin, excluding inventory write-off, restructuring and impairment impact

 

 

4.2%

 

 

7.9%

 

 

4.5%

 

 

7.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

430,145

 

$

498,772

 

$

1,286,532

 

$

1,480,491

NU SKIN ENTERPRISES, INC.

Reconciliation of Effective Tax Rate Excluding Impact of Inventory Write-off, Restructuring and Impairment to GAAP Effective Tax Rate

(in thousands, except for per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2024

 

2023

 

2024

 

2023

Provision (benefit) for income taxes

 

$

4,996

 

$

2,504

 

$

(6,760)

 

$

15,937

Impact of inventory write-off, restructuring and impairment on provision for income taxes

 

 

-

 

 

650

 

 

23,071

 

 

3,243

Provision for income taxes, excluding impact of inventory write-off, restructuring and impairment

 

$

4,996

 

$

3,154

 

$

16,311

 

$

19,180

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes

 

 

13,298

 

 

(34,451)

 

 

(117,249)

 

 

17,250

Impact of inventory write-off

 

 

-

 

 

65,728

 

 

-

 

 

65,728

Impact of restructuring and impairment

 

 

-

 

 

-

 

 

156,484

 

 

9,787

Income before provision for income taxes, excluding impact of inventory write-off, restructuring and impairment

 

$

13,298

 

$

31,277

 

$

39,235

 

$

92,765

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

 

37.6%

 

 

(7.3)%

 

 

5.8%

 

 

92.4%

Effective tax rate, excluding impact of inventory write-off, restructuring and impairment

 

 

37.6%

 

 

10.1%

 

 

41.6%

 

 

20.7%

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Inventory Write-off, Restructuring and Impairment to GAAP Earnings Per Share

(in thousands, except for per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2024

 

2023

 

2024

 

2023

Net income

 

$

8,302

 

$

(36,955)

 

$

(110,489)

 

$

1,313

Impact of inventory write-off

 

 

-

 

 

65,728

 

 

-

 

 

65,728

Impact of restructuring and impairment

 

 

-

 

 

-

 

 

156,484

 

 

9,787

Tax impact

 

 

-

 

 

(650)

 

 

(23,071)

 

 

(3,243)

Adjusted net income

 

$

8,302

 

$

28,123

 

$

22,924

 

$

73,585

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share

 

$

0.17

 

$

(0.74)

 

$

(2.23)

 

$

0.03

Diluted earnings per share, excluding inventory write-off, restructuring and impairment impact

 

$

0.17

 

$

0.56

 

$

0.46

 

$

1.47

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding (000)

 

 

49,733

 

 

49,859

 

 

49,645

 

 

50,029

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

December 31, 2024

 

Year ended

December 31, 2024

 

 

Low end

 

High end

 

Low end

 

High end

Earnings Per Share

 

$

(0.09)

 

$

0.01

 

$

(2.32)

 

$

(2.22)

Impact of restructuring and impairment expense:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring and impairment

 

 

0.40

 

 

0.40

 

 

3.55

 

 

3.55

Tax impact

 

 

(0.12)

 

 

(0.12)

 

 

(0.58)

 

 

(0.58)

Adjusted EPS

 

$

0.19

 

$

0.29

 

$

0.65

 

$

0.75

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107526723/en/

Media: media@nuskin.com, (801) 345-6397 Investors: investorrelations@nuskin.com, (801) 345-3577